Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 1, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Quality indicator set for systemic sclerosis.

Dinesh Khanna1, Otylia Kowal-Bielecka, Puja P Khanna

  • 1Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA. dkhanna@mednet.ucla.edu

Clinical and Experimental Rheumatology
|May 19, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement.

Seminars in arthritis and rheumatism·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseases.

Annals of the rheumatic diseases·2026
Same author

Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseases.

Biochemistry and biophysics reports·2026
Same author

Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy.

RMD open·2026
Same author

Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study.

Seminars in arthritis and rheumatism·2026
Same journal

The expanded cardiovascular risk prediction score as a cardiovascular mortality predictor in rheumatoid arthritis.

Clinical and experimental rheumatology·2026
Same journal

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Clinical and experimental rheumatology·2026
Same journal

Clinical features and gastrointestinal bleeding risk factors in IgA vasculitis patients: a retrospective study in a large volume centre.

Clinical and experimental rheumatology·2026
Same journal

Reply to the comment on: The microbiota in axial spondyloarthritis: what have we learned from Mendelian randomisation studies?

Clinical and experimental rheumatology·2026
Same journal

Comprehensive evaluation of bone structural and microarchitectural changes in rheumatoid arthritis treated with baricitinib using HR-pQCT, imaging, and biomarker analyses.

Clinical and experimental rheumatology·2026
Same journal

Tracking interstitial lung disease in systemic sclerosis: integrating lung magnetic resonance imaging into a clinically oriented multimodal follow-up strategy.

Clinical and experimental rheumatology·2026
See all related articles

Thirty-two quality indicators (QIs) were developed to assess and enhance care for Systemic Sclerosis (SSc) patients. These QIs cover diagnosis, follow-up, and treatment, aiming to improve patient outcomes and inform healthcare policy.

Area of Science:

  • Rheumatology
  • Health Services Research
  • Clinical Quality Measurement

Background:

  • Systemic Sclerosis (SSc) presents significant economic burdens, including high treatment costs and reduced productivity.
  • Ensuring consistent, high-quality care for SSc patients is crucial, yet the extent to which current treatment strategies are consistently applied is unknown.
  • Quality indicators (QIs) are essential for evaluating the process-of-care quality in SSc, defining standards for patient eligibility and recommended care.

Purpose of the Study:

  • To develop a comprehensive set of Quality Indicators (QIs) for the diagnosis, management, and treatment of Systemic Sclerosis (SSc).
  • To establish measurable standards for evaluating the quality of care provided to SSc patients.
  • To provide a foundation for improving SSc patient outcomes and informing healthcare policy.

More Related Videos

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Jun 1, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Main Methods:

  • A systematic literature review on SSc diagnosis and treatment was conducted.
  • Proposed QIs were evaluated by a national Expert Panel (n=9) using the RAND/UCLA methodology, integrating literature review with expert consensus.
  • The finalized QIs were presented to members of the Scleroderma Clinical Trials Consortium (SCTC) for further validation.

Main Results:

  • Thirty-two valid QIs for SSc care were established by the Expert Panel.
  • The QI set comprises 9 for initial diagnosis, 12 for ongoing management, and 11 for treatment of SSc.
  • SCTC experts confirmed the validity of all 32 QIs, with general agreement on the availability of recommended tests, procedures, and treatments.

Conclusions:

  • A rigorous methodology yielded 32 validated QIs for Systemic Sclerosis (SSc) care.
  • These QIs provide a robust framework for assessing and improving the quality of care for SSc patients.
  • The developed QIs can inform policy decisions aimed at optimizing SSc patient care and outcomes.